Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
| 1.46 | |
| 1.46 | |
| - | |
| 1.46 | |
| 1.4599 | |
| 1.3464-5.4491 | |
| 40 104 M | |
| 203 M | |
| 5 902 K | |
| -0.5342 | |
| 1.016 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0....
Participants Carl Spana; President, CEO and Director; Palatin Technologies Inc Steve Wills; CFO, COO, Treasurer and Secretary; Palatin Technologies Inc Joe Pantginis; Analyst; H.C. Wainwright & Co ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
